Journal
AMERICAN JOURNAL OF EPIDEMIOLOGY
Volume -, Issue -, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/aje/kwac032
Keywords
cohort studies; coronavirus disease 2019; COVID-19; severe acute respiratory syndrome coronavirus 2
Categories
Funding
- National Heart, Lung, and Blood Institute (NHLBI)-Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) [OT2HL156812]
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA) [R01 AG066162]
- NHLBI, National Institutes of Health (NIH), US Department of Health and Human Services [75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005]
- NHLBI [U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917, U01 HL089897, U01 HL089856, N01-HC-25195, HHSN268201500001I, 75N92019D00031, HHSN268201300001I/N01-HC-65233, R01HL093009]
- National Institute on Deafness and Other Communication Disorders [U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917]
- NINDS [R01 NS102715]
- NHLBI
- University of Alabama at Birmingham [HHSN268201800005I, HHSN268201800007I]
- Northwestern University [HHSN268201800003I]
- University of Minnesota [HHSN268201800006I]
- Kaiser Foundation Research Institute [HHSN268201800004I]
- COPD Foundation
- University of Miami [HHSN268201300004I/N01-HC-65234]
- Albert Einstein College of Medicine [HHSN268201300002I/N01-HC-65235]
- University of Illinois at Chicago [HHSN268201300003I/N01-HC-65236]
- San Diego State University [HHSN268201300005I/N01-HC-65237]
- National Institute of Dental and Craniofacial Research
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH Office of Dietary Supplements
- Jackson State University [HHSN268201800013I]
- Tougaloo College [HHSN268201800014I]
- Mississippi State Department of Health [HHSN268201800015I]
- University of Mississippi Medical Center [HHSN268201800010I, HHSN268201800011I, HHSN268201800012I]
- National Institute on Minority Health and Health Disparities
- National Center for Research Resources
- National Center for Advancing Translational Sciences
- NIH, through University of California, San Francisco-Clinical and Translational Science Institute grant [UL1RR024131]
- MESA
- NHLBI (A) [75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161]
- NIA [R01 AG066162, R01-AG058969, U01 NS041588]
- National Center for Advancing Translational Sciences [UL1-TR-000040, UL1-TR-001079, UL1-TR-001420]
- NHLBI (c) [N02-HL-64278, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167]
- Environmental Protection Agency [RD831697, RD-83830001]
- Broad Institute of MIT [3U54HG003067-13S1]
- Broad Institute of Harvard [3U54HG003067-13S1]
- TOPMed Informatics Research Center [3R01HL-117626-02S1, HHSN268201800002I, HHSN268201600034I, HHSN268201600032I, HHSN268201600038I]
- TOPMed Data Coordinating Center [3R01HL-120393, U01HL-120393, HHSN268180001I]
- National Center for Advancing Translational Sciences, Clinical and Translational Science Institute [UL1TR001881]
- National Institute of Diabetes and Digestive and Kidney Diseases Diabetes Research Center [DK063491]
- NIH/NHLBI [R21HL153700, K23HL130627, R21HL129924, R21HL121457, U10 HL109164, U10 HL109257, U10 HL109146, U10 HL109172, U10 HL109250, U10 HL109168, U10 HL109152, U10 HL109086]
- NINDS ( A) [U01 NS041588, R01 NS29993, R01 NS48134]
- NIH [Z01-ES101947, R01-HL095393, RC2-HL1011715, R21/33-HL120770, R01-HL097163, Z01-HL134585, UH2/3-HL123442, P01-HL092870, UG3/UH3-HL151865]
- DoD [W81XWH-17-1-0597]
- AstraZeneca
- Boehringer-Ingelheim
- Genentech
- GlaxoSmithKline
- MedImmune, Inc. (Gaithersburg, Maryland)
- Novartis
- Regeneron Pharmaceuticals, Inc. (Tarrytown, New York)
- Sanofi S.A. (Paris, France)
- Teva Pharmaceuticals USA (North Wales, Pennsylvania)
- NIH/NHLBI (b) [HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, U01 HL137880, U24 HL141762]
- COPD Foundation by AstraZeneca
- MedImmune
- Bayer Corporation (Whippany, New Jersey)
- Bellerophon Therapeutics (Warren, New Jersey)
- Chiesi Farmaceutici S.p.A. (Parma, Italia)
- Forest Research Institute, Inc. (Jersey City, New Jersey)
- Grifols Therapeutics, Inc. (Research Triangle Park, North Carolina)
- Ikaria, Inc. (Hampton, New Jersey)
- Nycomed Pharma GmbH (Zurich, Switzerland)
- ProterixBio, Inc. (Billerica, Massachusetts)
- Regeneron
- Sanofi
- Sunovion
- Takeda Pharmaceutical Company (Tokyo, Japan)
- Theravance Biopharma, Inc. (South San Francisco, California)
- Mylan N.V. (White Sulphur Springs, West Virginia)
- NHLBI (d) [75N92019D00027, 75N92019D00028, 75N92019D00029, 75N92019D00030]
- Roche, Inc. (New York, New York)
- AMGen, Inc. (Thousand Oaks, California)
- GSK
- Merck
- Johnson & Johnson (New Brunswick, New Jersey)
- Knopp Biosciences LLC (Pittsburgh, Pennsylvania)
- Pieris Pharmaceuticals GmbH (Hallbergmoos, Germany)
- The NHLBI [N01-HC-95168, N01-HC-95169, R01-HL077612, R01-HL093081, R01-HL130506, R01-HL127028, R01-HL127659, R01-HL098433, R01-HL101250, R01-HL135009]
- [R01HL109315]
- [R01HL109301]
- [R01HL109284]
- [R01HL109282]
- [R01HL109319]
- [U01HL41642]
- [U01HL41652]
- [U01HL41654]
- [U01HL65520]
- [U01HL65521]
Ask authors/readers for more resources
The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a national prospective study comprising 14 established US cohort studies that aims to evaluate risk factors and outcomes of COVID-19, as well as assess the long-term societal and behavioral impact of the pandemic on health trajectories.
The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a national prospective study of adults comprising 14 established US prospective cohort studies. Starting as early as 1971, investigators in the C4R cohort studies have collected data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health. C4R links this pre-coronavirus disease 2019 (COVID-19) phenotyping to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and postacute COVID-related illness. C4R is largely population-based, has an age range of 18-108 years, and reflects the racial, ethnic, socioeconomic, and geographic diversity of the United States. C4R ascertains SARS-CoV-2 infection and COVID-19 illness using standardized questionnaires, ascertainment of COVID-related hospitalizations and deaths, and a SARS-CoV-2 serosurvey conducted via dried blood spots. Master protocols leverage existing robust retention rates for telephone and in-person examinations and high-quality event surveillance. Extensive prepandemic data minimize referral, survival, and recall bias. Data are harmonized with research-quality phenotyping unmatched by clinical and survey-based studies; these data will be pooled and shared widely to expedite collaboration and scientific findings. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and outcomes, including postacute sequelae, and assessment of the social and behavioral impact of the pandemic on long-term health trajectories.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available